search
Back to results

Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
placebo for gemfibrozil
gemfibrozil
Sponsored by
Elixir Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • non-smoker
  • Body mass index (BMI) of 19-28 kg/m2
  • no relevant food allergies

Exclusion Criteria:

  • any subject for whom gemfibrozil is contraindicated
  • any subject with a history of hypoglycemia or who tend to get easily hypoglycemic
  • clinically significant history of or current abnormality or disease of any organ system

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    2

    1

    Arm Description

    mitiglinide + gemfibrozil

    mitiglinide + placebo for gemfibrozil

    Outcomes

    Primary Outcome Measures

    pharmacokinetics of mitiglinide
    pharmacodynamics of mitiglinide

    Secondary Outcome Measures

    safety and tolerance of mitiglinide when co-administered with 600 mg gemfibrozil

    Full Information

    First Posted
    December 3, 2007
    Last Updated
    February 16, 2009
    Sponsor
    Elixir Pharmaceuticals
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00566865
    Brief Title
    Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil
    Official Title
    A Double-Blind, Placebo-Controlled Study to Assess the Effect of Gemfibrozil Co-Administration on the Pharmacokinetics and Pharmacodynamics of Mitiglinide in Healthy Volunteers
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2009
    Overall Recruitment Status
    Completed
    Study Start Date
    November 2007 (undefined)
    Primary Completion Date
    December 2007 (Actual)
    Study Completion Date
    December 2007 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Elixir Pharmaceuticals

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The primary objective of this study is to determine the extent of effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of mitiglinide.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes Mellitus

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Crossover Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    14 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    2
    Arm Type
    Experimental
    Arm Description
    mitiglinide + gemfibrozil
    Arm Title
    1
    Arm Type
    Placebo Comparator
    Arm Description
    mitiglinide + placebo for gemfibrozil
    Intervention Type
    Drug
    Intervention Name(s)
    placebo for gemfibrozil
    Intervention Description
    mitiglinide + placebo for gemfibrozil 600 mg bid
    Intervention Type
    Drug
    Intervention Name(s)
    gemfibrozil
    Intervention Description
    Mitiglinide + 600 mg gemfibrozil bid
    Primary Outcome Measure Information:
    Title
    pharmacokinetics of mitiglinide
    Time Frame
    3 days of treatment with gemfibrozil
    Title
    pharmacodynamics of mitiglinide
    Time Frame
    3 days of treatment with gemfibrozil
    Secondary Outcome Measure Information:
    Title
    safety and tolerance of mitiglinide when co-administered with 600 mg gemfibrozil
    Time Frame
    3 days of treatment with gemfibrozil

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    55 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: non-smoker Body mass index (BMI) of 19-28 kg/m2 no relevant food allergies Exclusion Criteria: any subject for whom gemfibrozil is contraindicated any subject with a history of hypoglycemia or who tend to get easily hypoglycemic clinically significant history of or current abnormality or disease of any organ system
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Erin Nulf, RN, BSN
    Organizational Affiliation
    Quintiles Phase I Services
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil

    We'll reach out to this number within 24 hrs